RxDoctor Payments Data

Mary Beck, PA

Physician Assistant · Lutherville, MDNPI 1629019948

Payments from drug & device makers

$2,679in general payments, 2019–2025

Across 91 payments — averaging $29.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$795
  • Sumitomo Pharma America, Inc.$621
  • Urovant Sciences Inc$318
  • Medtronic$286
  • Ambu Inc.$166
  • Hollister Incorporated$150
  • plus $343 from 6 others

What the payments were for

  • Food & beverage$2,679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast16$795
Sumitomo Pharma America, Inc.31$621
Urovant Sciences Inc12$318
Medtronic7$286
Ambu Inc.6$166
Hollister Incorporated5$150
AbbVie(2 entities)4$93
Boston Scientific3$74
180 Medical, Inc.2$62
Astellas Pharma US Inc2$46
Mission Pharmacal Company2$40
Integra Lifesciences Corporation1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,679 in reported general payments places this provider in the 85th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$60,337
Medicare patients
188
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron77$62,052
MyrbetriqMirabegron41$27,847
ElmironPentosan Polysulfate Sodium11$7,169
Solifenacin Succinate19$1,046
Oxybutynin Chloride ErOxybutynin Chloride14$891
Tamsulosin Hcl70$846
Dicyclomine Hcl29$353
Oxybutynin Chloride22$342
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$150
Fluconazole21$144
Ciprofloxacin Hcl19$116
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$621$62,05277 claims
Astellas Pharma US IncMyrbetriq$46$27,84741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →